ziekte van Parkinson en rustelood been syndroom Parkinson disease and Restless Legs Syndrome
Conditions
Interventions
On day 1 and 2, two different rotigotine formulation patches will be apllied
for the duration of 24 hours. These patches will be removed on day 2 and 3 and
determined what the difference in adhesive
Sponsors
UCB Pharma
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy males and females 18-55 years BMI 19-28 incl
Exclusion criteria
Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adhesiveness: the average adhesiveness score of 2 days of 24-hour patch application as rated by the investigator Safety: adverse events, vital signs, ECG-parameters, laboratory parameters, skin assessments, physical examination, the C-SSRS | — |
Secondary
| Measure | Time frame |
|---|---|
| Patch adhesiveness over 24 hours of patch application and immediately after patch application | — |
Countries
Netherlands
Outcome results
None listed